|
|
 |
|
|
|
|
|
|
Schering-Plough is a global
pharmaceutical company committed to researching, discovering, manufacturing
and marketing new therapies and treatment programs to ease suffering,
improve health and save lives. The company is a recognized leader
in biotechnology, genomics and gene therapy. Our pharmaceutical
product lines are complemented by leading brands in various consumer
and animal health categories.
But what we do is only part of who we are – the people and
culture behind the products are our driving force. Read on for a
better understanding of our commitment to diversity, career development
philosophy and corporate philanthropy.
Our Commitment to Diversity
Recognizing that our company’s success is tied directly to
the contributions of our employees, we appreciate the value of working
with people from a wide array of personal and professional backgrounds.
Our commitment to diversity
is reflected in every aspect of our
business, from recruitment activities and workplace training initiatives,
to procurement functions and community outreach programs.
Career Development
Ongoing professional development is extremely important at Schering-Plough.
One of our fundamental objectives is to provide you with the tools
and resources to maximize your growth potential. State-of-the-art
performance management and leadership development initiatives are
key to achieving this goal.
Further avenues for advancement and growth at Schering-Plough include
a competitive Educational Assistance Program as well as numerous
in-house training initiatives in sales, management, manufacturing
and other critical business areas. We actively encourage and support
our employees to increase their technical and leadership skill set
through participation in professional and industry related associations.
Corporate Philanthropy
We understand that we have a responsibility to the communities in
which we operate and we give back to them both through the Schering-Plough
Foundation and patient assistance and support programs. As well,
we encourage all employees to take part in philanthropic
activities.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
About Us
